ADCETRIS
Google image searchProduct monograph
Active ingredient
brentuximab vedotin, 50 MG/VIAL
DIN: 02401347
Dosage form(s): POWDER FOR SOLUTION
Route(s) of administration: INTRAVENOUS
Schedule: Prescription / Schedule D
Company: SEAGEN INC.
Date: 27-AUG-2021
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FX — Other monoclonal antibodies and antibody drug conjugates (ATC, ATC/DDD)
- L01FX05 — BRENTUXIMAB VEDOTIN (ATC/DDD)
Reference brand drug: Adcetris
Pharmaceutical standard: MFR
